Bacteria-derived peptide aurB halts prostate tumour growth by targeting mitochondrial energy production

Bacteria might have just handed prostate cancer researchers a new tool. The peptide aurB, isolated from bacteria, has been shown to stop prostate tumor growth by hitting cancer cells right where it hurts: their mitochondria. This isn’t just another “maybe someday” headline. Targeting mitochondrial energy production is a direct, disruptive move in the fight against cancer at the cellular level.

Here’s what matters for researchers:

For those tracking peptide-based innovation, this study is a wake-up call. There’s a lot more to explore in the intersection of microbiology and oncology. If you want to dig deeper into the full landscape of research peptides, check out the peptide research index.

Key takeaway: Bacteria are not just adversaries—they’re a source of novel peptides with game-changing applications. AurB is proof that peptide research isn’t slowing down. Watch this space; the next breakthrough might already be growing in a Petri dish.

Get inspired by what’s possible. The next aurB could be just a culture away.